Drug development company focused on the senolytic technology to fight age-related diseases
Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases.
When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.
Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.
Visit website: https://www.oisinbio.com/
Oisin Biotechnologies is also referenced in the following:
People at Oisin Biotechnologies
Founder and Chief Executive Officer at Oisín Biotechnologies
CSO Oision Biotechnologies, co-founder of Oisin Oncology and Chair in Prostate Cancer Research at the University of Alberta
Oisin Biotechnologies News
Longevity Technology interviews Aubrey de Grey about senolytics and other senotherapeutics
Longevity Technology - 05-Aug-2021
Most approaches have their limitations but good progress is being made on several frontsRead more...
Oisín raised $9.5M to advance senolytic therapies for kidney & age-related diseases
Longevity Technology - 28-May-2021
Investigational therapy on old mice cleared senescent cells up to 70%, extending life by 20%Read more...
LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020
Comprehensive review of companies' clinical and financial state of playRead more...
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...Read more...
OncoSenX raises more funds for cancer therapy, plans for clinical trial
GeekWire - 11-May-2020
Allowing developments on tech that will kill cancer based on their geneticsRead more...
Fight Aging! reports back from SENS Research Foundation Pitch Day
Fight Aging! - 20-Jan-2020
When some of these succeed in human trials even more money will pile in to fund further advancesRead more...
OncoSenX targets solid tumours with senolytics
Lifespan.io (LEAF) - 22-Oct-2019
Phase 1 clinical trial starting early 2020Read more...
SRF has made progress in the fight against ageing
Lifespan.io (LEAF) - 05-Dec-2017
R&D phase in SENS repair approach has shown promising resultsRead more...
False Positives in Senescent Cell Detection
Lifespan.io (LEAF) - 19-Aug-2017
Researchers commonly determine the presence of senescent cells through the use of the p16ink4a (p...Read more...
Hallmark of Aging Reversed by Senescent Cell Removal
Lifespan.io (LEAF) - 25-Mar-2017
Study directly targets one of the mechanisms that senescent cells use to avoid apoptosis, Focuse...Read more...
A Look at Ascendance Biomedical, Packaging Medical Tourism for Longevity Therapies
Fight Aging! - 28-Dec-2016
It is focused on the twofold path of (a) establishing patient-funded trials of potentially usefu...Read more...
Fight Aging predicts the sequence of arrival for meaningful antiaging therapies
Next Big Future - 01-Dec-2016
Each treatment will target a different type of molecular damage in cells and tissues. 1) Clearan...Read more...